Matinas BioPharma Holdings, Inc. Matinas BioPharma Holdings, Inc.

close
  • Home
  • LYPDISO™
    • LYPDISO™ Overview
    • Omega-3 Fatty Acids
  • LNC Technology
    • LNC Platform
    • MAT2203
    • MAT2501
  • About Us
    • Company Overview
    • Leadership
    • News
  • Investors
    • Investors Overview
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • Governance
  • Contact

Press Releases

Investors

Investors

  • Investors Overview
  • News & Events
    • News & Events Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Company Info Overview
    • Executive Team
    • Presentations
    • Contacts
  • Financial Info
    • Financial Info Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • SEC Filings Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Governance Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
News & Events

News & Events

  • News & Events Overview
  • Press Releases
  • IR Calendar
  • Email Alerts
  • News & Events

  • News & Events Overview
  • Press Releases
  • IR Calendar
  • Email Alerts
Jan 06, 2021 7:00am EST

Matinas BioPharma to Present at the ICR Conference 2021

Jan 04, 2021 7:00am EST

Matinas BioPharma Announces FDA Conditional Acceptance of LYPDISO™ as the Brand Name for MAT9001

Dec 07, 2020 6:35am EST

Matinas BioPharma Announces Collaboration with the National Institute of Allergy and Infectious Diseases to Evaluate Oral Formulations of Gilead’s Antiviral Remdesivir Utilizing Matinas’ LNC Platform Delivery Technology

Dec 07, 2020 6:30am EST

Matinas BioPharma Files Preliminary Proxy for Special Meeting of Stockholders

Dec 01, 2020 7:00am EST

Matinas BioPharma Appoints Hui Liu, Ph.D., M.B.A. as Chief Technology Officer

Nov 20, 2020 7:00am EST

Matinas BioPharma Awarded up to $3.75 Million from the Cystic Fibrosis Foundation to Support Development of Oral Amikacin (MAT2501) for the Treatment of NTM Infections in Cystic Fibrosis Patients

Nov 19, 2020 4:15pm EST

Matinas BioPharma to Participate in Annual Piper Sandler Healthcare Conference

Nov 06, 2020 7:00am EST

Matinas BioPharma Reports Third Quarter 2020 Financial Results and Operational Highlights

Oct 23, 2020 7:30am EDT

Matinas BioPharma to Webcast Conference Call Discussing Third Quarter 2020 Financial and Operational Results on November 6, 2020

Oct 19, 2020 6:30am EDT

Matinas BioPharma Announces Unanimous DSMB Approval to Progress into Second Cohort of Patients in the EnACT Study of MAT2203 (Oral Amphotericin B) for the Treatment of Cryptococcal Meningitis

RSS
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • ...19
Next
Matinas BioPharma Holdings, Inc.

Science

  • LYPDISO™ (MAT9001)
  • MAT2203
  • MAT2501
  • LNC PLATFORM

Investors

  • COMPANY PROFILE
  • STOCK DATA
  • ANALYST COVERAGE
  • GOVERNANCE
  • PRESS RELEASES
  • EVENTS
  • PRESENTATIONS
  • SEC FILINGS

Company

  • OVERVIEW
  • OUR TEAM
  • NEWS
  • CAREERS
  • CONTACT US

Register for updates

Follow Us

LinkedIn facebook twitter
© 2021 Matinas BioPharma Holdings, Inc. All Rights Reserved.